Table 1.
Baseline characteristics grouped by CD8 status (N=48)
| Characteristics | All | 10-20% (n=35) | > 20% (n=13) |
|---|---|---|---|
| Age, years | |||
| Median (IQR) | 50 (39-60) | 49 (38-58) | 52 (46-60) |
| < 40 | 12 (25.0) | 10 (28.6) | 2 (15.4) |
| ≥ 40 | 36 (75.0) | 25 (71.4) | 11 (84.6) |
| Disease status | |||
| Metastatic, de novo | 16 (33.3) | 9 (25.7) | 7 (53.8) |
| Metastatic, recurrent | 31 (64.6) | 26 (74.3) | 5 (38.5) |
| TFI 6-12 months | 15 (31.3) | 12 (34.3) | 3 (23.1) |
| TFI >12 months | 16 (33.3) | 14 (37.1) | 2 (15.4) |
| Locally inoperable advanced | 1 (2.1) | 0 (0) | 1 (7.7) |
| ECOG performance status | |||
| 0 | 18 (37.5) | 11 (31.4) | 7 (53.8) |
| 1 | 30 (62.5) | 24 (68.6) | 6 (46.2) |
| Baseline disease | |||
| 0 | 15 (31.2) | 8 (22.9) | 7 (53.8) |
| 1 | 31 (64.6) | 25 (71.4) | 6 (46.2) |
| NA | 2 (4.2) | 2 (5.7) | 0 (0) |
| Number of metastatic sites | |||
| < 3 | 25 (52.1) | 18 (51.4) | 7 (53.8) |
| ≥ 3 | 23 (47.9) | 17 (48.6) | 6 (46.2) |
| Metastatic site | |||
| Lung | 24 (50.0) | 19 (54.3) | 5 (38.5) |
| Liver | 10 (20.8) | 8 (22.9) | 2 (15.4) |
| Bone | 19 (39.6) | 16 (45.7) | 3 (23.1) |
| Neo/adjuvant chemotherapy | |||
| Any | 32 (66.7) | 26 (74.3) | 6 (46.2) |
| Anthracycline | 30 (62.5) | 24 (68.6) | 6 (46.2) |
| Taxane | 29 (60.4) | 23 (65.7) | 6 (46.2) |
| Platinum | 6 (12.5) | 6 (17.1) | 0 (0) |
| Capecitabine | 5 (10.4) | 3 (8.6) | 2 (15.4) |
| PD-L1 status | |||
| Positive | 17 (35.4) | 9 (25.7) | 8 (61.5) |
| Negative | 13 (27.1) | 10 (28.6) | 3 (23.1) |
| Unknown | 18 (37.5) | 16 (45.7) | 2 (15.4) |
Data are presented as No. (%) unless otherwise indicated
Abbreviation: ECOG Eastern Cooperative Oncology Group, TFI treatment-free interval, PD-L1 programmed death-ligand 1